Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

An Important Question in Prostate Cancer Treatment Answered at ESMO

An Important Question in Prostate Cancer Treatment Answered at ESMO

Hormone therapy has been known to work in prostate cancer since the 1940s. However, until this year we had not found a satisfactory answer to the question: what is the best initial treatment for high-risk advanced prostate cancer ? Prostate cancer raised this important question: is the answer “combined new-generation hormonal therapy” or “conventional hormonal therapy together with chemotherapy”? Extensive clinical research compared them, and analyses found similar efficacy for these two treatment approaches.

This Result Was Important in Two Respects: 

  • First, compared with a treatment such as chemotherapy that is difficult to administer and manage for side effects, adding the new-generation hormonal treatment Abiraterone to easier-to-manage conventional hormone therapy proved as effective as chemotherapy, a development that pleased us.
  • Second, after Abiraterone, a new-generation hormonal treatment, had results announced in June at 2017 ASCO, the two successful studies raised the possibility that the routine chemotherapy we offer patients might be worse than the hormone therapy combination, because we would be unable to use this treatment as a first option for a long time, as it was not yet approved in our country. The scientists conducting the study interpreted the results as meaning that because the two treatment strategies are similar in efficacy, there is no objection to preferring the available treatment option .

Study Details

STAMPEDE, a specially designed study that had previously shown the efficacy of the chemotherapy docetaxel and hormonal treatment abiraterone in prostate cancer, compared these two agents this time. In this part of the research, results from patients enrolled between 2011 and 2013, totaling 566, were analyzed and presented at ESMO 2017. Of the patients, 189 received docetaxel and 377 received abiraterone.

You may be interested in:

The study aimed to compare overall survival with these two treatment approaches, and, as noted above, no significant difference was found in survival outcomes.

For initial treatment of advanced high-risk prostate cancer, adding docetaxel chemotherapy or abiraterone to standard hormonal therapy was compared not only in survival but also in side effects, and the frequency of serious side effects was similar.

Conclusion

For a patient with advanced prostate cancer, if two treatments have similar efficacy, the one offering better quality of life and fewer side effects should be preferred; however, an accessible, approved and cheaper treatment can also be chosen with confidence.

You May Be Interested In:

Sources

ESMO 2017 Press Release: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments.
esmo.org - 08 Sep 2017

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

An Important Question in Prostate Cancer Treatment Answered at ESMO

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy